Abstract
Osteoarthritis is the most common form of arthritis and includes manifestations of both nociceptive and neuropathic mechanisms. Intravenous lignocaine, a sodium channel blocker and neuronal membrane stabiliser, has been shown in controlled trials to be effective in neuropathic pain; however, the outcome of intravenous lignocaine in osteoarthritis patients has not been assessed yet. The existence of a neuropathic component to the pain of osteoarthritis was investigated by examining possible benefits upon sensory aspects of pain in osteoarthritis patients receiving intravenous lignocaine therapy. Retrospective observational study was carried out using health data routinely collected for non-research purposes. Patients with generalised osteoarthritis who had not responded to more conservative treatments were recruited sequentially and scheduled for intravenous lignocaine therapy either in the rheumatology or pain relief departments. Assessment of efficacy was carried out through a questionnaire including sensory, psychological and social aspects of pain. The sample consisted of 17 women (60.7 %) and 11 men (39.3 %) with an average age at the time of treatment of 59 ± 11 years. The average pain relief calculated from the NRS scores was 30.2 ± 21.4 %, and the mean duration of pain relief was 10 ± 6 weeks. Pain intensity (p < 0.001), pain relief (p < 0.003) and mobility (p < 0.003) were all significantly improved after administration of lignocaine intravenous infusion therapy. Pain was significantly reduced in a group of osteoarthritis patients after administration of intravenous lignocaine. This suggests that part of the pain mechanism in this patient group may be neuropathic, appears to contribute significantly to the patients’ pain, and requires further investigation in studies designed specifically for the purpose.
Similar content being viewed by others
References
Arden N, Nevitt MC (2006) Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 20(1):3–25
Felson DT (2005) Relation of obesity and of vocational and avocational risk factors to osteoarthritis. J Rheumatol 32(6):1133–1135
Dray A, Read SJ (2007) Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 9(3):212
Bjordal JM, Ljunggren AE, Klovning A, Slørdal L (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329(7478):1317
Neame R, Zhang W, Doherty M (2004) A historic issue of the annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis 63(8):897–900
Catterall WA (2002) Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp 241:206–218
Kastrup J, Petersen P, Dejgård A, Angelo HR, Hilsted J (1987) Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain 28(1):69–75
Rowbotham MC, Reisner-Keller LA, Fields HL (1991) Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41(7):1024–1028
Mao J, Chen LL (2000) Systemic lidocaine for neuropathic pain relief. Pain 87(1):7–17
Burch F, Codding C, Patel N, Sheldon E (2004) Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthr Cartil 12(3):253–255
Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE (2004) Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr Med Res Opin 20(suppl 2):S13–S19
Loughnan TE, Taverner MG, Webb A (2009) Randomized, double blinded comparative trial of intradermal injections of lignocaine versus N-saline around the knee to relieve pain in patients awaiting total knee replacement. Clin J Pain 25(4):269–272
Altman RD (1991) Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl 27:10–12
Raphael JH, Southall JL, Kitas GD (2003) Adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. Rheumatology 42(1):185–186
Dworkin RH, Turk DC, Farrar JT et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1–2):9–19
Cohen J (1992) A power primer. Psychol Bull 112(1):155–159
Dworkin RH, Turk DC, Wyrwich KW et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105–121
Koppert W, Zeck S, Sittl R, Likar R, Knoll R, Schmelz M (1998) Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans. Anesthesiology 89(6):1345–1353
Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M (2000) Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 85(1–2):217–224
Dray A (2008) New horizons in pharmacologic treatment for rheumatic disease pain. Rheum Dis Clin N Am 34(2):481–505
Hochman JR, French MR, Bermingham SL, Hawker GA (2010) The nerve of osteoarthritis pain. Arthrit Care Res 62(7):1019–1023
Im H, Kim J, Li X et al (2010) Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis Rheum 62(10):2995–3005
Zhang W, Doherty M, Leeb BF et al (2007) EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 66(3):377–388
Felson DT, Lawrence RC, Hochberg MC et al (2000) Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med 133(9):726–737
Wandel S, Jüni P, Tendal B et al (2010) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341:c4675
Hawker GA (2009) Experiencing painful osteoarthritis: what have we learned from listening? Curr Opin Rheumatol 21(5):507–512
Rosemann T, Laux G, Szecsenyi J, Wensing M, Grol R (2008) Pain and osteoarthritis in primary care: factors associated with pain perception in a sample of 1,021 patients. Pain Med 9(7):903–910
Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67(12):1716–1723
Raphael JH, Southall JL, Treharne GJ, Kitas GD (2002) Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord 3:21
Acknowledgments
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duarte, R.V., Raphael, J.H., Dimitroulas, T. et al. Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model. Rheumatol Int 34, 315–320 (2014). https://doi.org/10.1007/s00296-013-2893-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-013-2893-y